Lipid-lowering Therapy for Secondary Prevention in Patients Undergoing Elective Percutaneous Coronary Intervention (PCI)

AstraZeneca

Status: Terminated

Conditions: Coronary Artery Disease

Study type: Observational

Funder types: Industry

Identifiers

NCT01190072

NIS-CSI-DUM-2010/1

Details and patient eligibility

About

The purpose of the study is to follow the management of blood lipids in patients with planned percutaneous coronary intervention (widening of coronary vessels) in a period from 6 to 10 weeks after the intervention.

Enrollment: 120 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or nonpregnant female
• Coronary patient hospitalised for elective PCI
• Hypercholesterolaemia defined as LDL-C ≥ 2 mmol/L

Exclusion criteria

• Any chronic inflammatory condition
• Chronic anti-inflammatory pharmacotherapy (except low-dose ASA)